Leukemia Lymphoma B Cell 3 Cn375896
A B-cell cancer affecting the blood and lymphatic system. Symptoms may include fever, night sweats, and enlarged lymph nodes. Treatment depends on the stage and may involve chemotherapy, radiation, or stem cell transplant.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Easy bruising
Lymphadenopathy
Night sweats
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Splenomegaly
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Bruton Tyrosine Kinase Inhibitors
Oral targeted therapy that blocks signaling pathways essential for B-cell survival and proliferation. Provides effective disease control with generally favorable side effect profile compared to traditional chemotherapy.
Medication management with follow-up
Active treatment with regular monitoring by a healthcare provider is recommended.
B-Cell Receptor Pathway Inhibitors
Targeted agents that interrupt critical signaling pathways in B-cell receptor function, leading to decreased cancer cell survival. Often used in combination with other agents for enhanced efficacy.
Additional treatment options
Radiation Therapy
Localized radiation treatment used primarily for symptomatic disease control, bulky tumor masses, or as part of conditioning regimen before stem cell transplantation. Targeted approach minimizes exposure to surrounding tissues.
procedureResponse-Adapted Monitoring
Personalized monitoring strategy based on individual treatment response patterns and disease characteristics. Includes regular imaging, laboratory assessments, and clinical evaluations tailored to disease trajectory.
monitoringPsycho-Oncology Support
Specialized psychological support addressing anxiety, depression, and coping challenges common in hematologic malignancies. Includes individual counseling, support groups, and stress management techniques.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Leukemia Lymphoma B Cell 3 Cn375896?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Leukemia Lymphoma B Cell 3 Cn375896. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy